Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Cannabidiol  COVID-19 treatment studies for Cannabidiol  C19 studies: Cannabidiol  Cannabidiol   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19
Malinowska et al., International Journal of Molecular Sciences, doi:10.3390/ijms22041986 (Review)
Malinowska et al., Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19, International Journal of Molecular Sciences, doi:10.3390/ijms22041986 (Review)
Feb 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Review of the potential benefits and concerns for the use of cannabidiol in the treatment of COVID-19.
Malinowska et al., 17 Feb 2021, peer-reviewed, 4 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCannabidiolAll
Abstract: International Journal of Molecular Sciences Review Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19 † Barbara Malinowska 1, *,‡ , Marta Baranowska-Kuczko 1,2,‡ , Aleksandra Kicman 1 and Eberhard Schlicker 3, * 1 2 3 * † ‡ Department of Experimental Physiology and Pathophysiology, Medical University of Białystok, 15-222 Białystok, Poland; mabar@umb.edu.pl (M.B.-K.); olakicman@gmail.com (A.K.) Department of Clinical Pharmacy, Medical University of Białystok, 15-222 Białystok, Poland Department of Pharmacology and Toxicology, University of Bonn, 53127 Bonn, Germany Correspondence: bmalin@umb.edu.pl (B.M.); e.schlicker@uni-bonn.de (E.S.); Tel.: +48-85-748-5699 (B.M.) To the memory of our friend Professor Daniel Moura (Department of Pharmacology, University of Porto, Portugal), who was scientifically active in the field of ACE2 and angiotensin II. These authors contributed equally to this work. ijms22041986 Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may lead to coronavirus disease 2019 (COVID-19) which, in turn, may be associated with multiple organ dysfunction. In this review, we present advantages and disadvantages of cannabidiol (CBD), a non-intoxicating phytocannabinoid from the cannabis plant, as a potential agent for the treatment of COVID-19. CBD has been shown to downregulate proteins responsible for viral entry and to inhibit SARS-CoV-2 replication. Preclinical studies have demonstrated its effectiveness against diseases of the respiratory system as well as its cardioprotective, nephroprotective, hepatoprotective, neuroprotective and anti-convulsant properties, that is, effects that may be beneficial for COVID-19. Only the latter two properties have been demonstrated in clinical studies, which also revealed anxiolytic and antinociceptive effects of CBD (given alone or together with ∆9 -tetrahydrocannabinol), which may be important for an adjuvant treatment to improve the quality of life in patients with COVID-19 and to limit post-traumatic stress symptoms. However, one should be aware of side effects of CBD (which are rarely serious), drug interactions (also extending to drugs acting against COVID-19) and the proper route of its administration (vaping may be dangerous). Clearly, further clinical studies are necessary to prove the suitability of CBD for the treatment of COVID-19. Academic Editor: William C. Keywords: ACE2; cannabidiol; COVID-19; SARS-CoV-2; respiratory disease   Citation: Malinowska, B.; Baranowska-Kuczko, M.; Kicman, A.; Schlicker, E. Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19 †. Int. J. Mol. Sci. 2021, 22, 1986. https://doi.org/10.3390/ (Trey) Putnam Received: 11 January 2021 Accepted: 12 February 2021
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit